[go: up one dir, main page]

MX2017003892A - Tratamiento del sindrome de rett. - Google Patents

Tratamiento del sindrome de rett.

Info

Publication number
MX2017003892A
MX2017003892A MX2017003892A MX2017003892A MX2017003892A MX 2017003892 A MX2017003892 A MX 2017003892A MX 2017003892 A MX2017003892 A MX 2017003892A MX 2017003892 A MX2017003892 A MX 2017003892A MX 2017003892 A MX2017003892 A MX 2017003892A
Authority
MX
Mexico
Prior art keywords
rett syndrome
treating
treatment
methods
autism spectrum
Prior art date
Application number
MX2017003892A
Other languages
English (en)
Inventor
Tonks Nicholas
Krishnan Navasona
Original Assignee
Cold Spring Harbor Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Laboratory filed Critical Cold Spring Harbor Laboratory
Publication of MX2017003892A publication Critical patent/MX2017003892A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se relaciona con agentes y métodos para tratar los trastornos del espectro del autismo, tales como el Síndrome de Rett.
MX2017003892A 2014-09-25 2015-09-23 Tratamiento del sindrome de rett. MX2017003892A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055433P 2014-09-25 2014-09-25
US201562185214P 2015-06-26 2015-06-26
PCT/US2015/051594 WO2016049110A1 (en) 2014-09-25 2015-09-23 Treatment of rett syndrome

Publications (1)

Publication Number Publication Date
MX2017003892A true MX2017003892A (es) 2018-01-30

Family

ID=55581927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003892A MX2017003892A (es) 2014-09-25 2015-09-23 Tratamiento del sindrome de rett.

Country Status (11)

Country Link
US (2) US20170296561A1 (es)
EP (1) EP3197904B1 (es)
JP (1) JP2017531629A (es)
KR (1) KR20170070068A (es)
AU (3) AU2015320748A1 (es)
CA (1) CA2962406A1 (es)
ES (1) ES2927649T3 (es)
IL (1) IL251350A0 (es)
MX (1) MX2017003892A (es)
RU (1) RU2017110868A (es)
WO (1) WO2016049110A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105950774A (zh) * 2016-07-11 2016-09-21 江苏医诺万细胞诊疗有限公司 一种基于二代测序检测Rett综合症致病基因SNP位点的试剂盒及其检测方法
CN110225754A (zh) * 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
FI3574091T3 (fi) 2017-01-30 2023-05-03 Brainvectis Ekspressiovektori kolesterolin 24-hydrolaasia varten polyglutamiinin toiston spinoserebellaariataksioiden hoidossa
WO2020234363A2 (en) * 2019-05-21 2020-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome
CN119837883A (zh) * 2025-01-02 2025-04-18 暨南大学 中药单体化合物在改善孤独症样行为中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
US5786213A (en) 1996-04-18 1998-07-28 Board Of Regents, The University Of Texas System Inhibition of endogenous gastrin expression for treatment of colorectal cancer
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6709817B1 (en) 1999-09-07 2004-03-23 Baylor College Of Medicine Method of screening Rett syndrome by detecting a mutation in MECP2
NZ522045A (en) 2000-03-30 2007-05-31 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
IL155991A0 (en) 2000-12-01 2003-12-23 Max Planck Gesellschaft Rna interference mediating small rna molecules
US20040191926A1 (en) * 2001-09-26 2004-09-30 Zhong-Yin Zhang Ptp1b inhibitors and ligands
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
JP2008050263A (ja) * 2004-11-11 2008-03-06 Univ Kurume Ｒｅｔｔ症候群を治療する医薬
JP2008520575A (ja) 2004-11-15 2008-06-19 セプタイア インコーポレイテッド プロテインチロシンホスファターゼ阻害剤およびその使用方法
AU2007303205A1 (en) 2006-10-03 2008-04-10 Tekmira Pharmaceuticals Corporation Lipid containing formulations
CA2689549A1 (en) 2007-06-08 2008-12-18 Massachusetts Institute Of Technology Igf for the treatment of rett syndrome and synaptic disorders
US20090176312A1 (en) 2007-12-04 2009-07-09 Selinfreund Richard H Biological and chemical test media and system
US8153777B2 (en) 2008-11-04 2012-04-10 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 5 expression by antisense oligonucleotides
WO2010126590A1 (en) 2009-04-27 2010-11-04 Cold Spring Harbor Laboratory Ptp1b inhibitors
GB201002627D0 (en) 2010-02-16 2010-03-31 Loxbridge Res Llp Aptamer based analyte detection method
US8980553B2 (en) 2011-04-02 2015-03-17 New England Biolabs, Inc. Methods and compositions for enriching either target polynucleotides or non-target polynucleotides from a mixture of target and non-target polynucleotides
EP2841067A4 (en) * 2012-04-25 2016-04-13 Univ California MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME

Also Published As

Publication number Publication date
AU2015320748A1 (en) 2017-04-20
KR20170070068A (ko) 2017-06-21
CA2962406A1 (en) 2016-03-31
AU2022202323A1 (en) 2022-04-28
EP3197904B1 (en) 2022-08-10
AU2022202323B2 (en) 2024-01-25
EP3197904A4 (en) 2018-05-16
AU2020202426A1 (en) 2020-05-07
WO2016049110A1 (en) 2016-03-31
ES2927649T3 (es) 2022-11-08
EP3197904A1 (en) 2017-08-02
US11660306B2 (en) 2023-05-30
JP2017531629A (ja) 2017-10-26
US20190247408A1 (en) 2019-08-15
US20170296561A1 (en) 2017-10-19
RU2017110868A (ru) 2018-10-25
IL251350A0 (en) 2017-05-29

Similar Documents

Publication Publication Date Title
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
PH12018500057A1 (en) Substituted oxopyridine derivatives
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
EP3995581A3 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
NZ723884A (en) Methods of treating alzheimer’s disease
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
PH12018500578A1 (en) Methods of treating inflammatory diseases
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA201491385A1 (ru) Соединения, ингибирующие металлоферменты
WO2016077639A3 (en) Nanovesicular therapies
WO2015200790A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
WO2014151456A3 (en) Treatment of inflammatory diseases
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
HK1243935A1 (zh) 有机化合物
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2017003892A (es) Tratamiento del sindrome de rett.
WO2016042561A3 (en) Downregulating mir-132 for the treatment of lipid related disorders
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
HK1243936A1 (zh) 有机化合物
WO2015138761A3 (en) Methods for treating peripheral nerve damage